Veloxis Pharmaceuticals A/S (CPH: VELO), a commercial-stage specialty pharmaceutical company committed to improving the lives of transplant patients, reported on Friday an increase in the company's capital by 6,486,060 new shares with a nominal value of DKK0.10 each, corresponding to nominally DKK648,606.

Reportedly, this capital increase is as a consequence of the exercise of warrants by current and former employees of the company granted under the company's warrant programme.

As a result of the employee's investment in the company, proceeds to Veloxis Pharmaceuticals A/S from the capital increase amount to DKK 4,748,963.96.

Also, the subscription price for the new shares is DKK 0.35 per share of nominal DKK0.10, with regard to 2,134,015 shares; DKK0.86 per share of nominal DKK 0.10, with regard to 2,103,330 shares; DKK0.94 per share of nominal DKK0.10, with regard to 1,000,000 shares; DKK0.95 per share of nominal DKK0.10, with regard to 473,994 shares; DKK1.01 per share of nominal DKK0.10, with regard to 555,833 shares; DKK1.06 per share of nominal DKK0.10, with regard to 200,000 shares; DKK1.12 per share of nominal DKK0.10, with regard to 10,000 shares and DKK2.06 per share of nominal DKK0.10, with regard to 8,888 shares.

These new shares will be listed on Nasdaq Copenhagen following registration of the capital increase with the Danish Business Authority, upon which the share capital of Veloxis Pharmaceuticals A/S will be DKK173,631,561.70 divided into shares of DKK0.10 each.

Each share of nominal DKK0.10 carries one vote at general meetings in Veloxis Pharmaceuticals A/S. In addition, these new shares give rights to dividend and other rights from the time of registration of the capital increase with the Danish Business Authority.

(EUR1.00=DKK7.45)